Original Article

Clustering of Deceased Patients with COVID-19 in Iran Based on Clinical Features in Hospitalization

Abstract

Background: Effective clinical care and identifying susceptibility to COVID-19-related mortality requires rapid recognition of risk factors and their relations with disease outcomes. This study aimed to cluster and identify various subgroups of COVID-19 patients and examine the relationship between these subgroups and the causes of death. Methods: This retrospective study assessed the risk factors contributing to COVID-19 patients’ death (n = 128) by evaluating deceased patients' demographic, clinical, and laboratory features and clustering various subgroups of individuals to investigate any correlation. Results: The mean age of deceived patients was 69.7 years, and the majority of them were male (65.6%). The levels of blood urea nitrogen, creatinine, alkaline phosphatase, erythrocyte sedimentation rate, lactate dehydrogenase, and C-reactive protein were high at admission and increased during the hospitalization. Shortness of breath (68%) and cough (62.5%) were the most common symptoms, and hypertension (50.8%) was the most common comorbidity among deceased patients. The clustering quality based on the underlying disease and symptoms was not acceptable. However, clustering based on vital signs showed significant differences in body temperature, pulse rate, respiratory rate and oxygen saturation (P<0.001). Furthermore, disseminated intravascular coagulation (DIC) was significantly higher in patients with weaker vital signs than those with better vital signs (15.36% vs. 0.0% P = 0.002). Conclusion: Older age, male sex, hypertension, and high inflammatory markers might be the risk factors for COVID-19-related mortality. Furthermore, considering that patients with poor vital signs were susceptible to develop DIC, prevention of these consequences might be helpful in COVID-19 management.

1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470-3.
2. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-COV-2: A systematic review and meta-analysis. Int Infect Dis. 2020;94:91-5.
3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054-62.
4. Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in china. JAMA Netw Open. 2020;3(4):e205619-e.
5. Du Y, Tu L, Zhu P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am J Respir Crit Care. 2020;201(11):1372-79.
6. Chen T, Wu D, Chen H, Yan W, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ. 2020;368:m1091.
7. Badedi M, Darraj H, Alnami AQ, et al. Epidemiological and clinical characteristics of deceased COVID-19 patients. Int J Gen Med. 2021;14:3809-19.
8. Nouri-Vaskeh M, Khalili N, Sharifi A, et al. Clinical Characteristics of Fatal Cases of COVID-19 in Tabriz, Iran: An Analysis of 111 Patients. Front Emerg Med. 2020;5(1):e12.
9. McLachlan GJ. Cluster analysis and related techniques in medical research. Stat Methods Med Res. 1992;1(1):27-48.
10. Bacher J., Wenzig K., Vogler M. SPSS Two Step cluster - a first evaluation. Univ. Erlangennürnb. 2004;23.
11. Zhang B, Zhou X, Qiu Y, et al. Clinical characteristics of 82 cases of death from COVID-19. PLoS One. 2020;15(7):e0235458.
12. Okwan-Duodu D, Lim EC, You S, Engman DM. TMPRSS2 activity may mediate sex differences in covid-19 severity. Signal Transduct Target Ther. 2021;6(1):100.
13. Du Y, Zhou N, Zha W, Lv Y. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: A meta-analysis. Nutr Metab Cardiovasc Dis. 2021;31(3):745-55.
14. Hoffmann M, Kleine-Weber H, Schroeder S, et al. Sars-cov-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80.e8.
15. Parit R, Jayavel S. Association of ace inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study. Eur J Pharmacol. 2021;896:173899.
16. Swamy S, Koch CA, Hannah-Shmouni F, Schiffrin EL, Klubo-Gwiezdzinska J, Gubbi S. Hypertension and COVID-19: Updates from the era of vaccines and variants. J Clin Transl Endocrinol. 2022;27:100285.
17. Savoia C, Volpe M, Kreutz R. Hypertension, a moving target in COVID-19: Current views and perspectives. Circ Res. 2021;128(7):1062-79.
18. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using Open SAFELY. Nature. 2020;584(7821):430-6.
19. Furci F, Caminati M, Senna G, Gangemi S. The potential protective role of corticosteroid therapy in patients with asthma and COPD against COVID-19. Clin Mol Allergy. 2021;19(1):19.
20. Ho FK, Petermann-Rocha F, Gray SR, et al. Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants. PLoS One. 2020;15(11):e0241824.
21. Rechtman E, Curtin P, Navarro E, Nirenberg S, Horton MK. Vital signs assessed in initial clinical encounters predict COVID-19 mortality in an NYC hospital system. Sci Rep. 2020;10(1):21545.
22. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-8.
23. Han Y, Zhang H, Mu S, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. Aging (Albany NY). 2020;12(12):11245-11258.
24. Nabavi S, Javidarabshahi Z, Allahyari A, et al. Clinical features and disease severity in an Iranian population of inpatients with COVID-19. Sci Rep. 2021;11(1):8731.
Files
IssueVol 11, No 1 (Winter 2023) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/jpc.v11i1.12636
Keywords
Cluster Analysis; COVID-19; Mortality; Risk Factors

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Shaseb E, Ghaffary S, Vaez H, Sarbakhsh P, Khani E. Clustering of Deceased Patients with COVID-19 in Iran Based on Clinical Features in Hospitalization. J Pharm Care. 2023;11(1):16-24.